We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · December 19, 2019

Overall Survival With Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Overall Survival With Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-Label, Phase 3 Trial
Lancet 2019 Dec 10;[EPub Ahead of Print], MV Mateos, M Cavo, J Blade, MA Dimopoulos, K Suzuki, A Jakubowiak, S Knop, C Doyen, P Lucio, Z Nagy, L Pour, M Cook, S Grosicki, A Crepaldi, AM Liberati, P Campbell, T Shelekhova, SS Yoon, G Iosava, T Fujisaki, M Garg, M Krevvata, Y Chen, J Wang, A Kudva, J Ukropec, S Wroblewski, M Qi, R Kobos, J San-Miguel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading